Completed studies Data updated on 17 May 2017
No Study Name/Phase Type Sponsor Population (Gender/Age) Screened Enrolled. (Retention rate) Period
1 Carraguard/Phase III Microbicide PC ♀ 18-40 yrs 3604 2402 (86%) 2004-2007
2 FEM PreP/Phase III Oral Prep FHI360 ♀ 18-35 yrs 1306 764 (87.5%) 2009-2012
3 ACASI/Phase II Behavioral PC ♀ 18-40 yrs 390 200 (100%) 2007
4 SBC preparedness /Phase III Mapping FHI360 Community Mapping N/A >1000 2009-2012
5 HSV 2/Phase III HSV2 Treatment Norvartis ♀ ≥18 yrs 16 8 2008-2009
6 Diabetic Peripheral Neuropathic/Phase III Observational Pfizer ♂/♀ ≥18 yrs 8 8 (100%) 2011
7 Tyrosur study/Phase III Wound Healing Engelhard Arzneimittel ♂/♀ ≥12 yrs 55 55 (100%) 2012-2013
8 Impetigo/Phase III Impetigo Treatment Galderma Inc ♂/♀ ≥18 yrs 49 49 (100%) 2012-2013
9 PrEP & Risk Compensation/Phase III Behavioral FHI 360 ♀ 18-35 yrs 547 540 (100%) 2012-2013
10 PreP & Adherence /Phase III Behavioral FHI 360 ♀ 18-35 yrs 229 229 (100%) 2013
11 TESEC 05/Phase III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 167 164 (98.8%) 2012-2013
12 TESEC 07/Phase II/III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 66 64 (99%) 2012-2013
13 FACTS 001/Phase III Microbicide CONRAD ♀ 18-30 yrs 685 460 (89%) 2011-2015
14  Group B streptococcus/Phase III Observational Norvatis ♀ ≥18 yrs 501 501 2013-2015
15 CE/049/ACT/Phase IV Wound Healing Smith & Nephew ♂/♀ 0-65 yrs 12 12 (100%) 2015
16 TRIO MPT Acceptability RTI ♀ 18-35 yrs 170 140 2015 – 2016